JAK inhibitor ‘safe and effective’ for RA over 20 months
Extension trial in patients with inadequate response to methotrexate finds no new safety signals, researchers report
AusDoc brings you the latest news from the American College of Rheumatology virtual congress 2020.
The oral Janus kinase inhibitor upadacitinib remains safe and effective for treatment of rheumatoid arthritis (RA) for up to 84 weeks, European researchers say.
Speaking at ACR Convergence, the virtual congress of the American College of Rheumatology, Professor Josef Smolen of the Medical University of Vienna described the outcomes of a 70-week extension of the SELECT-MONOTHERAPY trial.
The original trial had demonstrated superior efficacy of upadacitinib to methotrexate over 14 weeks in 648 patients with RA (81% female, a mean of 6.6 years since diagnosis) and prior inadequate response to methotrexate, he said.
